Operating Segments

12 Months Ended

Dec. 31, 2015

Operating Segments [Abstract]

Operating Segments

Note 11. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended December 31,
	2015			2014
Revenues
Vaccines/BioDefense	$	8,754,418		$	6,756,388
BioTherapeutics		13,972			286,628
Total	$	8,768,390		$	7,043,016
Income (Loss) from Operations
Vaccines/BioDefense	$	1,263,709		$	807,164
BioTherapeutics		(4,487,988	)		(7,674,381	)
Corporate		(3,885,997	)		(3,894,132	)
Total	$	(7,110,276	)	$	(10,761,349	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,925		$	39,625
BioTherapeutics		199,661			199,196
Corporate		7,872			6,966
Total	$	247,458		$	245,787
Other Income (Expense), Net
Corporate	$	(1,209,887	)	$	3,437,505
Share-Based Compensation
Vaccines/BioDefense	$	111,960		$	114,920
BioTherapeutics		148,244			193,926
Corporate		394,277			411,304
Total	$	654,481		$	720,150

	As of December 31,
	2015		2014
Identifiable Assets
Vaccines/BioDefense	$	2,123,676	$	1,025,220
BioTherapeutics		76,183		204,308
Corporate		5,187,263		5,724,720
Total	$	7,387,122	$	6,954,248